CA2197466A1 - Compositions - Google Patents
CompositionsInfo
- Publication number
- CA2197466A1 CA2197466A1 CA002197466A CA2197466A CA2197466A1 CA 2197466 A1 CA2197466 A1 CA 2197466A1 CA 002197466 A CA002197466 A CA 002197466A CA 2197466 A CA2197466 A CA 2197466A CA 2197466 A1 CA2197466 A1 CA 2197466A1
- Authority
- CA
- Canada
- Prior art keywords
- physiologically tolerable
- composition
- manganese
- acid
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
On décrit une composition de milieu de contraste qui contient un composé à base de manganèse tolérable du point de vue physiologique, un promoteur d'absorption et un vecteur ou excipient tolérable du point de vue physiologique. Sa concentration en manganèse est d'au moins 0,3 mM mais elle peut aussi se présenter sous une forme galénique contenant au moins 300 µmol de manganèse. Le promoteur d'absorption comprend un composé réducteur, tolérable du point de vue physiologique, qui contient un groupe .alpha.-hydroxy cétone, un acide tolérable du point de vue physiologique et contenant des groupes .alpha. et/ou .beta.-hydroxy ou amino ou un de leurs sels, et/ou de la vitamine D. Ces compositions conviennent particulièrement pour l'imagerie du foie.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9416767.3 | 1994-08-18 | ||
GB9416768.1 | 1994-08-18 | ||
GB9416768A GB9416768D0 (en) | 1994-08-18 | 1994-08-18 | Compositions |
GB9416767A GB9416767D0 (en) | 1994-08-18 | 1994-08-18 | Compositions |
PCT/GB1995/001969 WO1996005867A2 (fr) | 1994-08-18 | 1995-08-18 | Compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2197466A1 true CA2197466A1 (fr) | 1996-02-29 |
Family
ID=26305478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002197466A Abandoned CA2197466A1 (fr) | 1994-08-18 | 1995-08-18 | Compositions |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0776219A2 (fr) |
JP (1) | JPH10504559A (fr) |
AU (1) | AU688565B2 (fr) |
CA (1) | CA2197466A1 (fr) |
FI (1) | FI970667A (fr) |
NZ (1) | NZ291479A (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5980863A (en) * | 1998-11-02 | 1999-11-09 | Eagle Vision Pharmaceutical Corporation | Manganese compositions and methods for MRI |
-
1995
- 1995-08-18 EP EP95929155A patent/EP0776219A2/fr not_active Withdrawn
- 1995-08-18 CA CA002197466A patent/CA2197466A1/fr not_active Abandoned
- 1995-08-18 AU AU32620/95A patent/AU688565B2/en not_active Ceased
- 1995-08-18 NZ NZ291479A patent/NZ291479A/en unknown
- 1995-08-18 JP JP8507869A patent/JPH10504559A/ja active Pending
-
1997
- 1997-02-17 FI FI970667A patent/FI970667A/fi unknown
Also Published As
Publication number | Publication date |
---|---|
NZ291479A (en) | 1999-04-29 |
FI970667A0 (fi) | 1997-02-17 |
JPH10504559A (ja) | 1998-05-06 |
AU3262095A (en) | 1996-03-14 |
FI970667A (fi) | 1997-02-17 |
EP0776219A2 (fr) | 1997-06-04 |
AU688565B2 (en) | 1998-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Gadolinium meets medicinal chemistry: MRI contrast agent development | |
US5628983A (en) | Squid magnetometry using paramagnetic metal chelates | |
CA2108362A1 (fr) | Agents a base de melamine pour ameliorer la qualite des images | |
JPH0768193B2 (ja) | 生理学的に認容性のnmr―造影剤用錯塩 | |
JPH082802B2 (ja) | 磁気共鳴イメージングに関する改良 | |
US20090317327A1 (en) | Aqueous Dispersion of Superparamagnetic Single-Domain Particles, Production and Use Thereof in Diagnosis and Therapy | |
JPH09502426A (ja) | 像コントラスト増強のための方法および組成物 | |
US5314681A (en) | Composition of positive and negative contrast agents for electron spin resonance enhanced magnetic resonance imaging | |
US6015545A (en) | Manganese containing magnetic resonance contrast agent | |
ES2289099T3 (es) | Compuestos a base de complejos de metal paramagnetico con ftalocianina y agente de contraste que los comprende. | |
WO1996005867A2 (fr) | Compositions | |
JP2002528473A (ja) | マンガン組成物及びmriのための方法 | |
US6136292A (en) | Determination of non-functioning areas of the g.i. tract using MRI of manganese composition | |
US5863519A (en) | Composition and method of MRI using both a positive and a negative contrast agent | |
US5716598A (en) | Contrast medium for magnetic resonance imaging using physiologically tolerable manganese compound | |
CA2197466A1 (fr) | Compositions | |
US5985245A (en) | Contrast agents for MRI using a manganese compound and kojic acid | |
WO1998011922A2 (fr) | Procede | |
US5368839A (en) | Insoluble salts of lanthanides for the visual display using nuclear magnetic resonance, of the gastro-intestinal tract | |
WO1993010821A1 (fr) | Procede et formulations utilises pour ameliorer l'examen des cavites du corps humain | |
WO1998011921A2 (fr) | Procede | |
Davis et al. | Optimization of a negative oral contrast agent for magnetic resonance imaging | |
WO2010099804A1 (fr) | Imagerie par résonance magnétique du foie | |
JPH03284629A (ja) | Mri用造影剤 | |
Miaux et al. | The value of gadoterate meglumine as a gastrointestinal contrast agent in MRI |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |